Secondary Logo

Institutional members access full text with Ovid®

Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer

Niazi, Tamima; Elakshar, Saraa; Stroian, Gabrielab

Current Opinion in Supportive and Palliative Care: September 2018 - Volume 12 - Issue 3 - p 351–358
doi: 10.1097/SPC.0000000000000371

Purpose of review The oligometastases is considered an intermediate state of the disease between localized and wide spread metastases. Local ablative therapy to oligometastatic prostate cancer is gaining significant traction and stereotactic body radiotherapy (SBRT) is an emerging treatment modality for this patient population. In this review, we report our literature review of SBRT to prostate oligometastases. Current evidence on the role of SBRT in oligometastatic prostate cancer reported in the last 10 years was summarized. Criteria for inclusion included studies with prostate cancer only as the primary site.

Recent findings The unique properties of the oligometastatic prostate cancer appear to carry a better prognosis than wide spread metastatic disease, especially if these metastases are amenable to local ablative therapies. Our literature review revealed that local ablative therapy, using SBRT to prostate oligometastases, is associated with significant 2-years local control and acceptable toxicity profile.

Summary SBRT to oligometastatic prostate cancer patients is feasible and carries an acceptable toxicity profile. The randomized phase II and III trials, currently underway, should clearly define the real benefit of this approach on progression-free and overall survival outcomes.

aDivision of Radiation Oncology, Department of Oncology

bDepartment of Medical Physics, Jewish General Hospital, McGill University, Montreal, Quebec, Canada

Correspondence to Tamim Niazi, MDCM, Division of Radiation Oncology, Department of Oncology, Jewish General Hospital, McGill University, Pavillon G, Room 002, 3755 Ch. De La Cote Sainte Catherine, Montreal, QC H3T 1E2, Canada. Tel: +1 514 340 8288; e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.